Florey Institute to Accelerate MND Drug Discovery with Novel iPSC Screening Platform
Key Insights
The Florey Institute (search) receives $5 million to advance drug screening for Motor Neurone Disease (search) (MND (search)) using a novel iPSC-based platform.
The platform uses iPSCs from over 100 MND (search) patients to screen potential treatments by assessing their ability to keep motor neurons alive.
Initial screenings accurately mirrored clinical trial outcomes, showing 95% of previously tested drugs were ineffective, validating the platform's accuracy.
The Florey Institute (search) of Neuroscience & Mental Health is set to revolutionize drug discovery for Motor Neurone Disease (search) (MND (search)) with a world-first drug screening technology. A $5 million grant from the Australian Medical Research Future Fund (MRFF) will enable large-scale screening of potential MND treatments using a platform based on induced pluripotent stem cells (iPSCs).
iPSC-Based Drug Screening
Dr. Chris Bye, the project leader, explained that the technology utilizes iPSCs derived from over 100 MND (search) patients, predominantly those with the sporadic form of the disease. These iPSCs can generate an unlimited supply of motor neurons exhibiting the key characteristic of MND: neuronal death. This allows researchers to test the efficacy of potential treatments by observing their ability to sustain motor neuron survival.
"We are then able to test whether potential treatments are able to keep motor neurons alive. We have already screened all the drugs tested in MND (search) patients, and our results matched what was found in trials – 95 per cent did not work," Dr. Bye stated.
Improving Clinical Trial Efficiency
The iPSC-based screening approach aims to enhance the quality of drug trials by identifying and eliminating ineffective drug candidates early in the development process. This could significantly reduce the number of failed clinical trials and accelerate the discovery of effective MND (search) treatments.
"Our breakthrough technology has the potential to revolutionise drug discovery for sporadic MND (search). We will be using it to conduct an unprecedented large-scale program of drug screening across high-value disease targets in MND," Dr. Bye added.
Addressing an Unmet Need
MND (search) is a devastating neurodegenerative disease affecting over 2,000 Australians, with an average survival rate of just over two years. Despite nearly 200 drugs being tested in human trials over the past 25 years, effective treatments remain elusive. This new technology offers a potential disruption to the traditional drug discovery model.
Health Minister Mark Butler emphasized the government's support for this innovative research, stating, "The Government is proud to support this innovative Australian research, which may unlock the potential for stem cell technologies to find an effective treatment for MND (search), by allowing therapies to be lab-tested with much greater speed and accuracy."
Collaborative Support
The Florey team's efforts have been supported by FightMND, the Victorian State Government, and Balcon Group, alongside a team of leading MND (search) clinicians, scientific experts, and key industry leaders. This collaborative approach positions the Florey Institute (search) to potentially deliver genuine therapeutics to clinical trials for MND patients.